Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.58 |
| ▸ | CTSS | P25774 | 7/20 | 0.54 |
| ▸ | CTSL | P07711 | 6/20 | 0.54 |
| ▸ | CTSB | P07858 | 4/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14434495 | 0.89 | CTSK (0.53) | CTSKCTSSCTSLCTSBALDH1A1 | |
| SCHEMBL10241673 | 0.88 | CA1 (0.51) | CTSKCTSSCTSLALDH1A1CA1 | |
| SCHEMBL20381057 | 0.87 | CTSK (0.66) | CTSKCTSSCTSLCTSBALDH1A1 | |
| SCHEMBL22144261 | 0.87 | CTSK (0.66) | CTSKCTSSCTSLCTSBALDH1A1 | |
| SCHEMBL11636918 | 0.84 | CA1 (0.63) | CTSKCTSSCTSLALDH1A1CA1 | |
| SCHEMBL16301413 | 0.82 | CTSK (0.52) | CTSKCTSSCTSLCTSBALDH1A1 | |
| SCHEMBL265783 | 0.81 | CTSK (0.66) | CTSKCTSSCTSLCTSBALDH1A1 | |
| SCHEMBL265461 | 0.81 | CTSK (0.66) | CTSKCTSSCTSLCTSBALDH1A1 | |
| SCHEMBL329038 | 0.81 | CTSK (0.66) | CTSKCTSSCTSLCTSBALDH1A1 | |
| SCHEMBL26195471 | 0.81 | CTSK (0.64) | CTSKCTSSCTSLCTSBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289471-A1 | NOVEL COMPOUNDS WITH HIGH THERAPEUTIC INDEX | SIGNATURE R&D HOLDINGS, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120289471-A1 | NOVEL COMPOUNDS WITH HIGH THERAPEUTIC INDEX | SIGNATURE R&D HOLDINGS, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-8173840-B2 | Compounds with high therapeutic index | SIGNATURE R&D HOLDINGS, LLC (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173840-B2 | Compounds with high therapeutic index | SIGNATURE R&D HOLDINGS, LLC (US) | 2012-05-08 | — | — | US | disclosed |
| WO-2007089745-A2 | NOVEL COMPOUNDS WITH HIGH THERAPEUTIC INDEX | SIGNATURE R & D HOLDINGS, LLC (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289471-A1 | NOVEL COMPOUNDS WITH HIGH THERAPEUTIC INDEX | IL4I1, SLC7A1, GOT1 | CTSK 903/4885CTSS 536/4885CTSL 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.